In the renal domain, studies spotlight FXR’s potential as a therapeutic asset for DN (Guo, Xie & Zhang, 2023; Luan et al., 2022), with our findings indicating its antifibrotic effect via Smad3 downregulation and Smad7 upregulation. Here, SMAD3 is linked to liver dysplastic nodule.